Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is developing a new, highly effective treatment for patients with cancer.   The approach uses a direct injection of the Company’s novel products to kill a patient’s primary tumors in situ.  The attenuated tumors then act as site to train the adaptive immune system to see out and destroy untreated tumors and metastases.  The Company expects to initiated human clinical trials in 2016 in the US and Canada.